13.86
前日終値:
$14.04
開ける:
$14.27
24時間の取引高:
13,766
Relative Volume:
1.28
時価総額:
$978.87M
収益:
$370.44M
当期純損益:
$12.19M
株価収益率:
80.44
EPS:
0.1723
ネットキャッシュフロー:
$50.74M
1週間 パフォーマンス:
+0.65%
1か月 パフォーマンス:
+12.87%
6か月 パフォーマンス:
-25.92%
1年 パフォーマンス:
+38.60%
Pharming Group Nv Adr Stock (PHAR) Company Profile
Compare PHAR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
PHAR
Pharming Group Nv Adr
|
13.86 | 978.87M | 370.44M | 12.19M | 50.74M | 0.1723 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharming Group Nv Adr Stock (PHAR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-12-09 | 開始されました | Jefferies | Buy |
Pharming Group Nv Adr (PHAR) 最新ニュース
Pharming Q1 2026 slides: Joenja growth offset by RUCONEST decline - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR) - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Pharming earnings in focus: Can rare disease growth offset Q1 dip? - Investing.com
Form 6K Pharming Group NV For: 28 May By Investing.com - Investing.com South Africa
PHARPharming Group NV ADR Stock Price and Quote - Finviz
Pharming Group gears up to report Q4 earnings: What's in the cards? - MSN
PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) - ChartMill
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges - Investing.com India
Pharming Group Q1 Earnings Call Highlights - Barchart.com
Earnings call transcript: Pharming Group Q1 2026 sees stock drop amid revenue decline - Investing.com
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 - GlobeNewswire Inc.
Pharming earnings in focus: Can rare disease growth offset Q1 dip? By Investing.com - Investing.com South Africa
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Decline in Short Interest - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Decline in Short Interest - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Pharming Group N.V. Investigated by the Portnoy Law Firm - GlobeNewswire
Pharming (NASDAQ: PHAR) updates 20-F with corrected CEO/CFO certifications - Stock Titan
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 33.9% in March - MarketBeat
Pharming Group (NASDAQ:PHAR) Given Buy Rating at HC Wainwright - defenseworld.net
HC Wainwright Estimates Pharming Group Q3 Earnings - Defense World
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short Interest - MarketBeat
Pharming Group Nv Adr (PHAR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):